不同剂量贝伐单抗在荷结肠癌细胞裸鼠中对伊立替康分布的影响

目的 观察不同剂量贝伐单抗对荷结肠癌细胞裸鼠中伊立替康分布的影响。方法 接种人结肠癌DLD-1细胞的裸鼠24只，随机分为4组。对照组：0.9%氯化钠溶液+伊立替康；实验1组：2.5 mg/kg贝伐单抗联合伊立替康治疗；实验2组：5 mg/kg贝伐单抗联合伊立替康治疗；实验3组：10 mg/kg贝伐单抗联合伊立替康治疗。观察不同组经处理后的肿瘤大小，外周血及肿瘤组织内伊立替康浓度的差异。结果 对照组及3个实验组间肿瘤体积差异比较无统计学意义。外周血中伊立替康的浓度在3个实验组中均明显高于对照组，且浓度随着贝伐单抗剂量增加而增加（432.33±104.76）、（409.69±267.15）、（719.21±253.00）vs. （299.69±83.63）ng/ml]。其中实验3组与实验2组、对照组的差异有统计学意义（P=0.045, 0.010）。肿瘤组织内伊立替康的浓度在3个实验组均明显低于对照组，其中实验3组与对照组的差异有统计学意义（P=0.047）。结论 贝伐单抗的治疗能改变伊立替康在荷结肠癌细胞裸鼠中分布，并与贝伐单抗的剂量有关。

Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts

Objective To investigate the effects of different doses of bevacizumab on irinotecan distribution in nude mice bearing human colon cancer cell xenografts. Methods DLD-1 human colon cancer cells were inoculated into 24 nude mice, which were randomly divided into four groups: control group, with 0.9% NaCl on d1, 5, 9 and irinotecan on d10; test group 1 to 3, with bevacizumab 2.5, 5 and 10 mg/kg respectively on d1, 5, 9 and irinotecan on d10. Tumor volume and irinotecan concentration in peripheral blood and xenograft tumor tissues in the four groups after treatment were analyzed. Results No significant difference in tumor volume was observed among groups. Irinotecan concentration in peripheral blood in the three test groups was significantly higher than that in the control group, and increased in a dose-dependent manner(432.33±104.76), (409.69±267.15) and (719.21±253.00) vs. (299.69±83.63)ng/ml], moreover, there were significant difference between test group 3 and test group 2, control group (P=0.045, 0.010). Irinotecan concentrations in tumor tissues from the test groups were lower than that in the control group, and there was significant difference between test group 3 and control group (P=0.047). Conclusion Bevacizumab might influence irinotecan distribution in nude mice bearing colon cancer cells in a dose-dependent manner.